Clinical Cancer Research Targets AACR Membership
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Benny, O.
Right arrow Articles by Machluf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benny, O.
Right arrow Articles by Machluf, M.
Clinical Cancer Research Vol. 11, 768-776, January 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Continuous Delivery of Endogenous Inhibitors from Poly(Lactic-Co-Glycolic Acid) Polymeric Microspheres Inhibits Glioma Tumor Growth

Ofra Benny1, Maayan Duvshani-Eshet1, Theresa Cargioli4, Lorenzo Bello2, Andreas Bikfalvi3, Rona S. Carroll4 and Marcelle Machluf1

1 Laboratory of Cancer Drug Therapeutics and Mammalian Cell Technology, Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa, Israel; 2 Molecular Mechanisms of Angiogenesis, Universite de Bordeaux I, Talence, France; 3 Department of Neurological Sciences, University of Milan, Milan, Italy; and 4 Laboratory of Neurosurgical Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: Marcelle Machluf, Laboratory of Cancer Drug Therapeutics and Mammalian Cell Technology, Faculty of Biotechnology and Food Engineering, Technion-Israel Institute of Technology, Haifa, Israel. Phone: 972-4-8294916/3079; Fax: 972-4-8293399; E-mail: machlufm{at}tx.technion.ac.il.

Purpose: There is an urgent need for modalities that can localize and prolong the administration of the antitumor agents, particularly antiangiogenic, to achieve long-term tumor inhibition. However, one of the major obstacles is designing a device in which the biological activity of sensitive endogenous inhibitors is retained. We have designed a biodegradable polymeric device, which provides a unique and practical means of localizing and continuously delivering hemopexin (PEX) or platelet factor 4 fragment (PF-4/CTF) at the tumor site while maintaining their biological activity. The potential and efficacy of this system is shown in vitro and in vivo in a human glioma mouse model.

Experimental Design: Polymeric microspheres made of poly(lactic-co-glycolic acid) (PLGA) were loaded with very low amounts of PEX and PF-4/CTF. The release profiles of these factors from PLGA and their biological activity were confirmed in vitro using proliferation assays done on endothelial and tumor cells. Tumor inhibition using this system was studied in nude mice bearing a human s.c. glioma.

Results: PEX and PF-4/CTF released in vitro from PLGA microspheres were biologically active and significantly inhibited the proliferation of human umbilical vein endothelial cells, bovine capillary endothelial cells, and U87-MG cells. A single local s.c. injection of PLGA microspheres loaded with low amounts of PEX or PF-4/CTF resulted in an 88% and 95% reduction in glioma tumor volume 30 days post-treatment. Immunohistochemical analysis of the treated tumors showed a marked decrease in tumor vessel density compared with untreated tumors.

Conclusion: Our findings show that polymeric microspheres are a very promising approach to locally and efficiently deliver endogenous inhibitors to the tumor site leading to a significant inhibition of the tumor.

Key Words: Brain tumor • angiogenesis • PEX • PF-4/CTF • controlled delivery




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
O. Benny, L. G. Menon, G. Ariel, E. Goren, S.-K. Kim, C. Stewman, P. M. Black, R. S. Carroll, and M. Machluf
Local Delivery of Poly Lactic-co-glycolic Acid Microspheres Containing Imatinib Mesylate Inhibits Intracranial Xenograft Glioma Growth
Clin. Cancer Res., February 15, 2009; 15(4): 1222 - 1231.
[Abstract] [Full Text] [PDF]


Home page
J R Soc InterfaceHome page
Y. Zhong and R. V Bellamkonda
Biomaterials for the central nervous system
J R Soc Interface, September 6, 2008; 5(26): 957 - 975.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
O. Benny, S.-K. Kim, K. Gvili, I. S. Radzishevsky, A. Mor, L. Verduzco, L. G. Menon, P. M. Black, M. Machluf, and R. S. Carroll
In vivo fate and therapeutic efficacy of PF-4/CTF microspheres in an orthotopic human glioblastoma model
FASEB J, February 1, 2008; 22(2): 488 - 499.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Duvshani-Eshet, O. Benny, A. Morgenstern, and M. Machluf
Therapeutic ultrasound facilitates antiangiogenic gene delivery and inhibits prostate tumor growth
Mol. Cancer Ther., August 1, 2007; 6(8): 2371 - 2382.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.